Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study
Authors
Schnippel, KNdjeka, N
Maartens, G
Meintjes, G
Master, I
Ismail, N
Hughes, J
Ferreira, H
Padanilam, X
Romero, R
Te Riele, J
Conradie, F
Issue Date
2018-07-09Submitted date
2018-07-17
Metadata
Show full item recordJournal
Lancet Respiratory MedicineAbstract
Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Following a compassionate access programme and local regulatory approval, the South African National Tuberculosis Programme began widespread use of bedaquiline in March, 2015, especially among patients with extensively drug resistant tuberculosis for whom no other effective treatment options were available. We aimed to compare mortality in patients on standard regimens with that of patients on regimens including bedaquiline.Publisher
ElsevierPubMed ID
30001994Language
enISSN
2213-2619ae974a485f413a2113503eed53cd6c53
10.1016/S2213-2600(18)30235-2
Scopus Count
Collections
Related articles
- Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
- Authors: Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E
- Issue date: 2018 Feb
- Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
- Authors: Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P
- Issue date: 2018 May
- Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
- Authors: Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, Leslie J, Boulle A, Mudaly V, Kock Y, Meintjes G, Wasserman S
- Issue date: 2019 Apr 24
- Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
- Authors: Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, Conradie F, Diacon AH, Ntinginya NE, Everitt DE, Haraka F, Li M, van Niekerk CH, Okwera A, Rassool MS, Reither K, Sebe MA, Staples S, Variava E, Spigelman M
- Issue date: 2019 Dec
- Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
- Authors: Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J, MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort.
- Issue date: 2015 Jan 15